Tensions Rise as AstraZeneca, EU Hold Vaccine Delivery Talks

BRUSSELS (AP) — The European Union's dispute with AstraZeneca intensified Wednesday with the Anglo-Swedish drugmaker denying the EU's assertion that it had pulled out of talks on vaccine supplies.

AstraZeneca said in a statement that it still planned to meet with EU officials in Brussels later in the day. The comments came after EU officials said the company had informed the bloc that it wouldn't take part in a meeting to discuss delayed vaccine commitments — the third such talks in as many days.

"The representative of AstraZeneca had announced this morning, had informed us this morning, that their participation is not confirmed, is not happening," said Dana Spinant, the EU Commission's spokeswoman.

The spat between AstraZeneca and the EU has raised concerns about vaccine nationalism, as countries desperate to end the pandemic and return to normalcy jockey for limited supplies of the precious vaccine shots.

The latest disagreement between the two sides came after AstraZeneca rejected the EU's accusation that the company had failed to honor its commitments to deliver coronavirus vaccines. AstraZeneca said the figures in its contract with the EU were targets that couldn't be met because of problems in rapidly expanding production capacity.

Chief Executive Pascal Soriot made the comments in an interview with the Italian newspaper La Repubblica following days of criticism from EU leaders furious about the news that initial shipments from AstraZeneca would be lower than anticipated.

The Anglo-Swedish drugmaker said last week that it planned to cut initial deliveries in the EU to 31 million doses from 80 million due to reduced yield in the manufacturing process.

"Our contract is not a contractual commitment,'' Soriot said. "It's a best effort. Basically we said we're going to try our best, but we can't guarantee we're going to succeed. In fact, getting there, we are a little bit delayed."

AstraZeneca said in a statement that it understands and shares "in the frustration that initial supply volumes of our vaccine delivered to the European Union will be lower than forecast."

On Monday, the EU threatened to impose tight export controls within days on Covid-19 vaccines made in the bloc.

The EU, which has 450 million citizens and the economic and political clout of the world's biggest trading bloc, is lagging badly behind countries like Israel and Britain in rolling out coronavirus vaccine shots for its health care workers and most vulnerable people. That's despite having over 400,000 confirmed virus deaths since the pandemic began.

The shortfall of planned deliveries of the AstraZeneca vaccine is coming at the same time as a slowdown in the distribution of Pfizer-BioNTech shots as that company upgrades production facilities at a plant in Belgium.

Meanwhile in north Wales, a pharmaceutical manufacturing company producing the Oxford-AstraZeneca vaccine had to partially evacuate its factory Wednesday after receiving a "suspicious package."

North Wales Police said they were dealing with the "ongoing incident" at the Wrexham Industrial Estate, 42 miles south of Liverpool. They closed the surrounding roads and asked residents to avoid the area until further notice. The force did not provide further details.

The U.K. arm of Mumbai-based pharmaceutical company Wockhardt said it notified authorities after receiving the package on Wednesday morning.

Wockhardt UK had struck an agreement with the British government, which reserved a production line at the Welsh plant to guarantee the supply of the Covid-19 vaccines. The company recently hosted British Prime Minister Boris Johnson, who hailed the agreement as a milestone in Britain's vaccine distribution program.

By RAF CASERT, Associated Press, and DANICA KIRKA, reporting from London.

Subscribe to Closing Arguments

Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.

Email *

Submit